Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
By the end of 2020, there were more than 8 million women alive who had received a breast cancer diagnosis in the previous 5 years, making it the most prevalent neoplasia in the world. About 70% of breast-cancer cases present positivity for estrogen and/or progesterone receptors and a lack of HER-2 o...
Main Authors: | Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/10/8488 |
Similar Items
-
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
by: Michele Iuliani, et al.
Published: (2022-02-01) -
Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01) -
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
by: Jiao Yang, et al.
Published: (2023-01-01) -
Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
by: Zhimin Zhu, et al.
Published: (2023-07-01) -
Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
by: Yan Mao, et al.
Published: (2023-01-01)